


**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the specification.

**Listing of Claims:**


Claim 1 (Original): A pharmaceutical composition comprising:

- (a) an anticholinergic selected from glycopyrronium bromide or an ester of a bi- or tricyclic amino alcohol of formula (I)



wherein:

Q is one of the groups -CH<sub>2</sub>-CH<sub>2</sub>-, -CH=CH-, or




R is methyl, ethyl, or propyl optionally substituted by fluorine or hydroxy,

R' is methyl, ethyl, or propyl, and

an equivalent of an anion X counters the positive charge of the N atom; and

Z is one of the groups



wherein:

Y is a single bond or an O atom,


R<sup>1</sup> is hydrogen, hydroxy, methoxy, ethoxy, propoxy, methyl, ethyl, propyl, hydroxymethyl, hydroxyethyl, or hydroxypropyl,

R<sup>2</sup> is a thienyl, phenyl, or cyclohexyl group, wherein these groups are optionally substituted by methyl, and thienyl and phenyl are optionally substituted by fluorine or chlorine, and

R<sup>3</sup> is hydrogen, or a thienyl or phenyl group which is optionally substituted by fluorine, chlorine, or methyl; and


- (b) a betamimetic selected from the group consisting of: formoterol; salmeterol; 4-hydroxy-7-[2-{[2-{[3-(2-phenylethoxy)propyl]sulfonyl}ethyl]amino}ethyl]-2(3*H*)-benzothiazolone; 1-(2-fluoro-4-hydroxyphenyl)-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol; 1-[3-(4-methoxybenzylamino)-4-hydroxyphenyl]-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol; 1-[2*H*-5-hydroxy-3-oxo-4*H*-1,4-benzoxazin-8-yl]-2-[3-(4-*N,N*-dimethylaminophenyl)-2-methyl-2-propylamino]ethanol; 1-[2*H*-5-hydroxy-3-oxo-4*H*-1,4-benzoxazin-8-yl]-2-[3-(4-methoxyphenyl)-2-methyl-2-propylamino]ethanol; 1-[2*H*-5-hydroxy-3-oxo-4*H*-1,4-benzoxazin-8-yl]-2-[3-(4-*n*-butyloxyphenyl)-2-methyl-2-propylamino]ethanol; and 1-[2*H*-5-hydroxy-3-oxo-4*H*-1,4-benzoxazin-8-yl]-2-{4-[3-(4-methoxyphenyl)-1,2,4-triazol-3-yl]-2-methyl-2-butylamino}ethanol, and a pharmacologically compatible acid addition salt thereof.

Claim 2 (Original): The pharmaceutical composition according to claim 1, wherein the anticholinergic is an ester of a bi- and tricyclic amino alcohol of formula (I)



wherein:

Q is one of the groups -CH<sub>2</sub>-CH<sub>2</sub>-, -CH=CH-, or




R is methyl or ethyl,

R' is methyl, and

anion X is bromide; and

Z is one of the groups



wherein:

R<sup>1</sup> is hydrogen, hydroxy, or hydroxymethyl,

R<sup>2</sup> is a thienyl, phenyl, or cyclohexyl group, and

R<sup>3</sup> is hydrogen, or a thienyl or phenyl group.

Claim 3 (Original): The pharmaceutical composition according to claim 1, wherein the anticholinergic is a salt of tiotropium.

Claim 4 (Original): The pharmaceutical composition according to claim 1, wherein the anticholinergic is tiotropium bromide.

Claim 5 (Original): The pharmaceutical composition according to claim 1, wherein the betamimetic is formoterol or salmeterol, or a pharmacologically compatible acid addition salt thereof

Claim 6 (Original): The pharmaceutical composition according to claim 1, wherein the anticholinergic is tiotropium bromide and the betamimetic is formoterol, or a pharmacologically compatible acid addition salt thereof.

Claim 7 (Original): The pharmaceutical composition according to claim 1, wherein the anticholinergic is tiotropium bromide and the betamimetic is salmeterol, or a pharmacologically compatible acid addition salt thereof.

Claim 8 (Original): The pharmaceutical composition according to claim 1, wherein the anion X is selected from the group consisting of: chloride, bromide, and methanesulfonate,

Claim 9 (Original): The pharmaceutical composition according to one of claims 1 to 8, wherein the pharmaceutical composition is an inhaled pharmaceutical composition.

Claim 10 (Original): A process for the production of a pharmaceutical composition according to one of claims 1 to 8, comprising:

- (a) mixing the anticholinergic and the betamimetic; and optionally
- (b) adding an adjuvant and/or carrier materials.

Claims 11-14 (Cancelled).